ImmuPharma plc (LON:IMM – Get Free Report) traded up 13.4% on Wednesday . The stock traded as high as GBX 10.80 and last traded at GBX 10.50. 7,242,426 shares changed hands during trading, a decline of 10% from the average session volume of 8,073,004 shares. The stock had previously closed at GBX 9.26.
ImmuPharma Trading Up 13.4%
The company has a 50-day moving average price of GBX 10.98 and a two-hundred day moving average price of GBX 5.43. The stock has a market cap of £52.79 million, a P/E ratio of -11.80 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Read More
- Five stocks we like better than ImmuPharma
- Using the MarketBeat Dividend Tax Calculator
- Carving Up Profits: 3 Food Stocks on the Thanksgiving Table
- Best Energy Stocks – Energy Stocks to Buy Now
- C3.ai’s Reset: Why New Leadership Could Spark a Turnaround
- How to trade using analyst ratings
- CleanSpark Secures $1.15B, Stock Drops—Here’s Why It’s an Opportunity
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
